✨
AI Summary
- Analysis of M&A targets: Viking, Verona, Altimmune.
- Discussion of Xenon and Crinetics as potential buyers.
- Insights into the biopharma M&A environment.
Guests on This Episode
EE
Edwin Elmhirst
2 podcast appearances
JH
Joseph Haas
4 podcast appearances
KG
Kevin Grogan
4 podcast appearances